Cargando…
Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析
OBJECTIVE: To observe the clinical efficacy and side effects of brentuximab vedotin (BV) plus chlormethine hydrochloride (CH) in patients with relapsed and refractory Hodgkin lymphoma (HL) after failure with BV alone. METHODS: From March, 2014 to December, 2014, 6 patients who failed with BV monothe...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342637/ https://www.ncbi.nlm.nih.gov/pubmed/26304081 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.07.010 |
_version_ | 1783555551272108032 |
---|---|
collection | PubMed |
description | OBJECTIVE: To observe the clinical efficacy and side effects of brentuximab vedotin (BV) plus chlormethine hydrochloride (CH) in patients with relapsed and refractory Hodgkin lymphoma (HL) after failure with BV alone. METHODS: From March, 2014 to December, 2014, 6 patients who failed with BV monotherapy were enrolled in this study. The chemotherapy regimen consisted of BV (1.2–1.8 mg/kg, iv. gtt, d1) and CH (6 mg/m(2), iv. gtt, d1) was given for 3 weeks as one course, and all patients received about 3–8 courses of chemotherapy, with an median of 4 courses. Clinical efficacy and adverse events were assessed and observed by radiographic examination and serological detection. RESULTS: Among 6 patients, the overall response rate was 100% with 2 complete remissionand 4 partial remission. The main adverse events were grade Ⅰ (2 patients) and Ⅳ (2 patients) bone marrow depression, grade Ⅱ (2 patients) gastrointestinal reaction, grade Ⅰ (1 patient) increase of transaminase and myocardial enzyme and grade I (1 patient) mouth ulcers. CONCLUSION: The combination of BV and CH in the treatment of relapsed and refractory HL after failure with BV alone was high effective and the toxicities were well tolerable. |
format | Online Article Text |
id | pubmed-7342637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73426372020-07-16 Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To observe the clinical efficacy and side effects of brentuximab vedotin (BV) plus chlormethine hydrochloride (CH) in patients with relapsed and refractory Hodgkin lymphoma (HL) after failure with BV alone. METHODS: From March, 2014 to December, 2014, 6 patients who failed with BV monotherapy were enrolled in this study. The chemotherapy regimen consisted of BV (1.2–1.8 mg/kg, iv. gtt, d1) and CH (6 mg/m(2), iv. gtt, d1) was given for 3 weeks as one course, and all patients received about 3–8 courses of chemotherapy, with an median of 4 courses. Clinical efficacy and adverse events were assessed and observed by radiographic examination and serological detection. RESULTS: Among 6 patients, the overall response rate was 100% with 2 complete remissionand 4 partial remission. The main adverse events were grade Ⅰ (2 patients) and Ⅳ (2 patients) bone marrow depression, grade Ⅱ (2 patients) gastrointestinal reaction, grade Ⅰ (1 patient) increase of transaminase and myocardial enzyme and grade I (1 patient) mouth ulcers. CONCLUSION: The combination of BV and CH in the treatment of relapsed and refractory HL after failure with BV alone was high effective and the toxicities were well tolerable. Editorial office of Chinese Journal of Hematology 2015-07 /pmc/articles/PMC7342637/ /pubmed/26304081 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.07.010 Text en 2015年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析 |
title | Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析 |
title_full | Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析 |
title_fullStr | Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析 |
title_full_unstemmed | Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析 |
title_short | Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析 |
title_sort | brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342637/ https://www.ncbi.nlm.nih.gov/pubmed/26304081 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.07.010 |
work_keys_str_mv | AT brentuximabvedotinliánhédànjièzhìliáoliùlìfùfānánzhìxìnghuòqíjīnlínbāliúliáoxiàofēnxī AT brentuximabvedotinliánhédànjièzhìliáoliùlìfùfānánzhìxìnghuòqíjīnlínbāliúliáoxiàofēnxī AT brentuximabvedotinliánhédànjièzhìliáoliùlìfùfānánzhìxìnghuòqíjīnlínbāliúliáoxiàofēnxī AT brentuximabvedotinliánhédànjièzhìliáoliùlìfùfānánzhìxìnghuòqíjīnlínbāliúliáoxiàofēnxī AT brentuximabvedotinliánhédànjièzhìliáoliùlìfùfānánzhìxìnghuòqíjīnlínbāliúliáoxiàofēnxī AT brentuximabvedotinliánhédànjièzhìliáoliùlìfùfānánzhìxìnghuòqíjīnlínbāliúliáoxiàofēnxī AT brentuximabvedotinliánhédànjièzhìliáoliùlìfùfānánzhìxìnghuòqíjīnlínbāliúliáoxiàofēnxī |